Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Sep 15, 2026; 18(9): 120472
Published online Sep 15, 2026. doi: 10.4251/wjgo.120472
Published online Sep 15, 2026. doi: 10.4251/wjgo.120472
Figure 1 Pathophysiology of irinotecan and 5-fluorouracil on ileal membrane phospholipid when enriched with eicosapentaenoic acid and docosahexaenoic acid.
CPT-11: Irinotecan; 5-FU: 5-fluorouracil; AA: Arachidonic acid; PLA2: Phospholipase A2; LOX: Lipoxygenase; COX: Cyclooxy genase; HETE: Hydroxyeicosatetraenoic acid; LTB4: Leukotriene-B4; PG: Prostaglandin; TX: Thromboxane; DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid; NE: Non-enzymatic; CYP: Cytochrome P450; HDoHE: Hydroxy-docosahexaenoic acid.
- Citation: Parsons SR, Rivas-Serna IM, Clandinin MT, Mazurak VC. Dietary eicosapentaenoic and docosahexaenoic acids decrease prostanoids in the ileum of rats treated with irinotecan and 5-fluorouracil. World J Gastrointest Oncol 2026; 18(9): 120472
- URL: https://www.wjgnet.com/1948-5204/full/v18/i9/120472.htm
- DOI: https://dx.doi.org/10.4251/wjgo.120472